Tel Aviv University system delivers therapy at site of mantle cell lymphoma

By
January 6, 2016 03:00
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

New research at Tel Aviv University offers significant hope of curing the most aggressive and presently incurable blood cancer called mantle cell lymphoma (MCL) and others like it. The promising and innovative system was found to successfully halt the proliferation of a cancer-related protein in white blood cells in both animal models and samples taken from MCL patients.

The study has just been published in the early edition of the Proceedings of the [US] National Academy of Sciences.

The research was led by Prof. Dan Peer of TAU ’s department of cell research and immunology and conducted by TAU doctoral students Shiri Weinstein and Itai Toker, in collaboration with Prof. Pia Raanani of Rabin Medical Center-Beilinson Campus in Petah Tikva and Prof. Arnon Nagler of Sheba Medical Center at Tel Hashomer.

With a median survival rate of just five to seven years, MCL is considered deadly and available therapies are scarce. Some 3,000 Americans and a few dozen Israelis are diagnosed with it in an average year.

Despite progress in personalized therapies to treat metastases elsewhere in the body, systemic therapeutic drug delivery to cancerous blood cells continues to challenge the world of cancer research.

Related Content

Breaking news
August 20, 2018
Russia urges rebels in Syria's Idlib to distance selves from Nusra Front

By REUTERS